Principal Financial Group
ONCT

Principal Financial Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Principal Financial Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,598
Closed -$44K – 2679
2022
Q1 		$44K Sell
1,598
-813
-34% -$29.6K ﹤0.01% 2491
2021
Q4 		$109K Sell
2,411
-1,819
-43% -$122K ﹤0.01% 2435
2021
Q3 		$353K Sell
4,230
-107
-2% -$8.85K ﹤0.01% 2263
2021
Q2 		$412K Buy
+4,337
New +$515K ﹤0.01% 2266
2013
Q3 		– Sell
-10
Closed -$90K – 2298
2013
Q2 		$90K Buy
+10
New +$77.1K ﹤0.01% 2212

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Principal Financial Group's ONCT Position: Q2 2022 in Review

Principal Financial Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 1,598 shares — an estimated $44K sold.

Principal Financial Group first reported a position in ONCT in Q2 2013 and held it in 5 quarters. The position peaked at $412K in Q2 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Principal Financial Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Principal Financial Group sold 1,598 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $44K.
  • Principal Financial Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
  • Principal Financial Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $412K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.